Journal article
I-Tositumomab in lymphoma.
Abstract
Radioimmunoconjugates are radioisotope-bound monoclonal antibodies that target radiation specifically to sites of lymphoma involvement. Initial studies of (131)I-tositumomab in non-Hodgkin lymphoma (NHL) have suggested benefit in patients with relapsed or refractory indolent disease. However, the routine adoption of this agent is tempered by concerns about associated toxicities and unclear long-term benefit. Based on a comprehensive search for …
Authors
Cheung MC; Maceachern JA; Haynes AE; Meyer RM; Imrie K; Members of the Hematology Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care
Journal
Curr Oncol, Vol. 16, No. 5, pp. 32–47
Publication Date
9 2009
DOI
10.3747/co.v16i5.385